Condition
B Cell Acute Lymphoblastic Leukemia (B-ALL)
Total Trials
4
Recruiting
4
Active
4
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 1 (1)
P 2 (2)
Trial Status
Recruiting4
Clinical Trials (4)
Showing 4 of 4 trials
NCT05480449Phase 1RecruitingPrimary
Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)
NCT06882057Phase 2Recruiting
Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol
NCT06785324Not ApplicableRecruiting
Study of Nutrition and Exercise in Adults Hospitalized for Treatment of Acute Lymphoblastic Leukemia (ALL)
NCT06764238Phase 2Recruiting
Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
Showing all 4 trials